About TreeFrog Therapeutics
TreeFrog Therapeutics is a French biotech company developing cell therapies using its proprietary C-Stem™ technology, which encapsulates and mass-produces induced pluripotent stem cells (iPSCs) in 3D microtissue capsules for scalable, high-quality manufacturing. Its pipeline targets neurodegeneration (Parkinson's disease), cardio-metabolic disorders, and immuno-oncology, with the goal of making safe and affordable cell therapies accessible to millions of patients.
Company details
Funding
Total raised
$84.2M
Last stage
Series B
Investors
Founders
Maxime Feyeux
Stem cell biologist; co-founded TreeFrog Therapeutics in 2018. Previously a postdoc at Institut des Maladies Neurodégénératives and maturation engineer at Aquitaine Science Transfert.
LinkedIn
Kevin Alessandri
Biophysicist; co-founded TreeFrog Therapeutics in 2018 in Bordeaux, France. Led the creation of the C-Stem technology platform and later relocated to Boston to head the US subsidiary.
LinkedInErwan Bezard
Scientific co-founder of TreeFrog Therapeutics, serving as Co-Founder and Consultant.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.